The Cholesterol Pill That Could Save Millions

Colorful pills and a rainbow ribbon on a pink background

A pill that cuts bad cholesterol by 60 percent without a needle could reshape how millions manage their heart disease risk, but the real test lies ahead.

Quick Take

Enlicitide, an experimental oral pill, reduced LDL cholesterol by 60 percent in a major phase 3 trial published February 4, 2026, matching the power of injectable drugs.
The drug targets the roughly 50 percent of high-risk patients whose cholesterol remains dangerously high despite maximum statin therapy.
Unlike injectable PCSK9 inhibitors approved around 2015, enlicitide offers a pill alternative that could boost patient adherence and access.
The FDA is reviewing enlicitide under priority status, while Merck funds a separate 14,000-patient trial to prove the drug prevents heart attacks and strokes.

The Cholesterol Problem That Never Went Away

Heart disease remains America’s leading killer, and high LDL cholesterol sits at the center of that tragedy. Statins, introduced in the late 1980s, revolutionized treatment by blocking the liver’s cholesterol production. Yet decades later, roughly half of high-risk patients still miss their LDL targets even on maximum statin doses. Their arteries continue accumulating plaque. Their risk of heart attack and stroke persists. Medicine needed a new answer.

Injectable PCSK9 inhibitors arrived around 2015, targeting a protein that regulates cholesterol clearance from the bloodstream. These drugs slashed LDL by 50 to 60 percent, matching what enlicitide now achieves. But adoption stalled. Patients balked at needles. Doctors wrestled with complex dosing schedules. Insurance companies hesitated over cost. Less than 10 percent of eligible patients ever received them. The breakthrough that should have transformed cardiology sat largely unused.

Enter the Pill That Changes the Game

Merck’s enlicitide flips the script by delivering PCSK9 inhibition in oral form. The CORALreef Lipids Trial enrolled over 2,900 high-risk patients already on statins—people with atherosclerosis or familial hypercholesterolemia whose cholesterol remained stubbornly elevated. At 24 weeks, enlicitide users achieved a 60 percent LDL reduction. At 52 weeks, that benefit held steady at 55 to 60 percent. Placebo patients, by contrast, saw their LDL rise by 3 to 9 percent. The drug also cut non-HDL cholesterol by 53 percent and reduced lipoprotein(a), a genetic risk factor, by 28 percent.

Safety data matched placebo. Serious adverse events occurred in roughly 10 to 12 percent of both groups over the trial period. Dr. Ann Marie Navar, the UT Southwestern cardiologist who led the trial, called it “the most effective oral LDL reduction since statins.” The results appeared in the New England Journal of Medicine, lending them credibility that extends far beyond Merck’s marketing department.

The Caveat That Keeps Cardiologists Awake

Here’s where hope collides with reality: enlicitide lowers cholesterol brilliantly, but nobody yet knows if it prevents heart attacks and strokes. Lowering cholesterol sounds straightforward, yet the leap from lab numbers to prevented deaths requires proof. Injectable PCSK9 inhibitors demonstrated that connection in long-term trials called FOURIER and ODYSSEY, showing real reductions in cardiovascular events. Enlicitide has not yet crossed that finish line.

Merck is running a separate outcomes trial involving 14,000 patients to answer that question, but results remain years away. Meanwhile, enlicitide requires empty-stomach dosing, a constraint that injectables avoid. The drug also remains untested in real-world settings where patients skip doses, forget instructions, and navigate the messy complexity of actual medical practice. Experts like Dr. William Boden of Boston University call the lipid data “compelling” but wisely counsel patience until the outcomes data arrives.

What Approval Could Mean for Millions

The FDA is reviewing enlicitide under priority status, suggesting potential approval within months. If that happens, a pill alternative to needles could finally unlock the PCSK9 market’s potential. Patients who fear injections might finally accept treatment. Doctors managing resistant cases would gain a tool that actually works. The $20 billion cholesterol drug market would shift, potentially lowering prices across the board as competition intensifies.

The broader impact hinges on one variable: whether outcomes match lipid effects. If enlicitide prevents cardiovascular events at rates matching injectable PCSK9s, the drug could prevent hundreds of thousands of heart attacks and strokes annually. If it does not, it becomes an expensive lipid-lowering agent with unproven clinical value. That distinction separates a genuine breakthrough from an elegant laboratory result.

For now, enlicitide represents progress where progress matters most—in addressing a stubborn, lethal problem that medicine has only partially solved. A pill beats a needle. A needle beats nothing. And nothing is what too many high-risk patients have chosen when faced with injectable PCSK9 inhibitors. Whether enlicitide finally closes that gap depends not on how well it lowers cholesterol, but on whether it saves lives.